Tag Archives: biologics
Biosimilars: How the EMEA Got It Right (Part 1)
I don’t think anyone disagrees that: Access to life-saving medications for all patients must be granted through a patient-focused, science-based application of a logical, open, and rational process, and that For patients to gain the greatest possible benefits, biologics with … Continue reading
Filed under Biosimilars Legislation
Biotech drugs: Pushing policy boundaries
Since the passage of the Medicare prescription drug benefit (Part D), Medicare policy and pricing decisions have taken on a role normally assigned to the market: the ongoing challenge to balance access considerations, the role and strength of evidence for efficacy and safety, and the cost of new treatments. Biotech medicines are under the spotlight for a number of reasons. Continue reading
